Cardiovascular

Blood pressure drug recalls soar

March 04, 2019

The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.

Popular blood pressure drug recalled

November 06, 2018

A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.

FDA denies claims for Zetia, Vytorin

February 17, 2016

FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.

FDA: Slightly elevated risk of cardiovascular, cerebrovascular issues with Xolair

September 29, 2014

An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug omalizumab (Xolair, Genentech) than in those who were not treated with omalizumab. As a result, FDA has added information about these potential risks to the drug label.

[BLOG] The acute coronary syndrome pipeline: Novel therapies targeting unmet needs in niche patient populations

August 19, 2014

Not surprisingly, the treatment costs associated with ACS and its various comorbidities are astoundingly high.

ADA: Canola oil can help control blood glucose in people with type 2 diabetes

June 17, 2014

Unhydrogenated, unsaturated vegetable oils, such as canola oil, can have health advantages when included in as part of a low-glycemic index (GI) diet in people with type 2 diabetes, according to research presented at American Diabetes Association Scientific Sessions in San Francisco, and published in Diabetes Care.

Novartis heart failure drug fails to win FDA approval

May 19, 2014

FDA has decided not to approve acute heart failure drug serelaxin (Novartis).

FDA approves Pradaxa for treatment, reduction in risk of recurrence of DVT, PE

April 09, 2014

FDA approved dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.

ACC: Bivalirudin associated with reductions in cardiac death, major bleeding in STEMI patients undergoing PCI

April 03, 2014

Compared to a combination of heparin and a glycoprotein (GP) IIb/IIIa inhibitor, use of bivalirudin (Angiomax) is associated with significant absolute reductions in risk for cardiac death and major non-coronary artery bypass graft (CABG) bleeding, according to data presented at the American College of Cardiology 63rd Annual Scientific Session (ACC.14), in Washington, D.C.

ACC: Evolocumab may help reduce LDL cholesterol levels

April 03, 2014

Results of 5 phase 3 studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood, were presented at the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14), in Washington, D.C

Study shows patient satisfaction with pharmacy program

June 01, 2013

Implementation of a pharmacy service that provides dosing, monitoring, education, and ensured safe transition from the inpatient to the outpatient setting is associated with improved patient satisfaction with overall care and with care related to anticoagulation management, according to a study published in the Annals of Pharmacotherapy.

Dietary fiber lowers risk of first stroke: Study

May 01, 2013

Greater dietary fiber intake is significantly associated with lower risk of first stroke, according to a recent study published in Stroke.

Greater awareness fuels increase in self-reported hypertension, use of antihypertensive medications

April 15, 2013

Thanks to consumer education efforts on heart disease and hypertension, self-reported hypertension and use of antihypertensive medications has increased in the United States according to the Centers for Disease Control and Prevention (CDC).

Health gains, cost savings seen with generic HF drugs

April 11, 2013

Guideline-directed medical therapy for heart failure (HF) is highly cost-effective and able to produce significant health gains for individuals with mild to moderate disease, according a study published April 2 in the Journal of the American College of Cardiology.

Long-term spironolactone use may improve heart function, but does not improve symptoms, quality of life for heart failure patients

April 01, 2013

In patients with heart failure with preserved ejection fraction, long-term treatment with spironolactone improved left ventricular diastolic function, but didn’t affect maximal exercise capacity, patient symptoms, or quality of life (QoL), according to a recent study in JAMA.

FDA issues second complete response letter for Xarelto

March 05, 2013

FDA has issued a second complete response letter regarding a supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Janssen) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS).

Adoption of evidence-based therapies associated with increased survival of STEMI patients

July 01, 2011

In a recently published observational registry study, researchers have demonstrated that the utilizatio of evidence-based therapies in patients experiencing ST-elevation myocardial infarction is on the rise.

FDA warns of adverse cardiovascular events associated with varenicline, notes label change

June 24, 2011

Safety information regarding varenicline will be added to the Warnings and Precautions section of the label and to the patient Medication Guide because smoking cessation aid varenicline may be associated with an increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease.

Angiotensin receptor blockers do not increase risk of cancer, FDA finds

June 17, 2011

Angiotensin receptor blockers do not increase the risk of developing cancer in patients using the medications, FDA announced recently after a safety review.